An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)

Trial Profile

An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Conbercept (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Acronyms FALCON
  • Sponsors Chengdu Kanghong Biotech
  • Most Recent Events

    • 22 Jan 2018 Sponsor association:However, the company tool also have added Chengdu Kanghong Biotech as a subsidiary of Chengdu Kanghong Pharmaceuticals. I have tagged Chengdu Kanghong Biotech as the sponsor to represent the details similar to CT.gov record.
    • 01 Sep 2017 Status changed to completed, according to results published in the Retina Journal.
    • 01 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top